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Combination Therapy in Asthma
Adel H. Mansur, Ph.D., FRCP,1 and Kirsten Kaiser, M.D.2
Abstract
Background: The long-term safety of a new asthma therapy combining fluticasone propionate and formoterol
fumarate (fluticasone/formoterol; Flutiform) was assessed.
Method: In an open-label study, mild to moderate-severe asthmatics ( ‡ 12 years; N¼472) were treated twice
daily with fluticasone/formoterol 100/10 lg (n¼224) or 250/10 lg (n¼248) for 6 months (n¼256) or 12 months
(n¼216). The primary and secondary objectives were the long-term safety and efficacy of fluticasone/formoterol,
respectively.
Results: In total, 413 (87.5%) patients completed the study (of which 175 participated for 12 months). Adverse
events (AEs) were reported by 174 patients (36.9%): 67 (29.9%) in the 100/10 lg group and 107 (43.1%) in the
250/10 lg group. The most common AEs ( > 2%) were nasopharyngitis, dyspnea, pharyngitis, and headache; the
majority were mild to moderate. Only 18 (3.8%) patients reported AEs considered study drug–related. Five
patients per group experienced 12 serious AEs; none was study medication–related. Asthma exacerbations were
reported by 53 patients (11.2%): 46 mild to moderate and nine severe. Clinical laboratory tests and vital signs
showed no abnormal trends or clinically important or dose-response–related changes. The efficacy analyses
showed statistically significant improvements at every time point throughout the study period at both doses.
Conclusion: Fluticasone/formoterol had a good safety and efficacy profile over the 6- and 12-month study
periods.
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Introduction
Asthma is a Chronic Disorder of the airways.
1–3 In-
haled corticosteroids (ICSs) are the mainstay of persis-
tent asthma therapy for targeting airway inflammation and
hyperresponsiveness. Long-acting b2-agonists (LABAs) allow
bronchodilation to be achieved for at least 12 hr2,4–6 and are
used together with ICSs as part of a stepwise treatment ap-
proach, when asthma is suboptimally controlled on ICSs
alone.2 For patients with persistent asthma, ICS/LABA com-
bination therapy has been shown to be clinically efficacious,
more so than either doubling the dose of ICS or administration
of ICSs in combination with other therapeutic agents.4,7–11 In
addition, in vitro research suggests that, at the molecular level,
there is a synergy between the therapeutic effects of ICSs and
LABAs when administered together.6,12–14 Moreover, in vivo
research on airway cells from patients with mild asthma sug-
gests that the combination of an ICS and a LABA shows en-
hanced effects compared with either drug alone.15
Despite significant advances in asthma management,16–21
poor control of symptoms and exacerbations persist for a
substantial proportion of patients. This may be a conse-
quence of inadequate drug delivery due to poor inhaler
technique, the choice of asthma therapy, or other factors such
as lack of patient adherence to prescribed treatment.1,22–27
The capacity for therapies to reach the small airways, which
are an important site of inflammation in asthma, may also
affect treatment efficacy.28,29 However, the clinical signifi-
cance of ICS/LABA deposition in the distal airways has not
yet been demonstrated.30,31
The ICS, fluticasone propionate (fluticasone), delivers a
potent and sustained anti-inflammatory effect.17,32–34 The
LABA, formoterol fumarate (formoterol), has a fast onset of
action and a prolonged bronchodilatory effect.5,35–38
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Fluticasone and formoterol have now been combined in a
single aerosol inhaler (fluticasone/formoterol; Flutiform).
This study assessed the long-term safety and efficacy of this
new combination aerosol in adolescents and adults with
mild to moderate-severe asthma.’
Materials and Methods
Study design
This was a long-term (up to 12 months), open-label study
assessing the safety and efficacy of fluticasone/formoterol
100/10lg and 250/10 lg, administered twice daily (b.i.d.).
The study was conducted in five European countries (Ger-
many, Hungary, Poland, Romania, United Kingdom;
EudraCT number: 2005-003518-14; US NCT number:
NCT00394121), in accordance with ICH Good Clinical
Practice (GCP), the Declaration of Helsinki, the European
Union Clinical Trials Directive (2001/20/EC), the GCP Di-
rective (2005/28/EC), and the prevailing local laws and
customs of the participating countries. Independent Ethics
Committees at each center reviewed and approved the pro-
tocol, and written informed consent was obtained from all
patients, or the parents or legal guardians of those patients
below 18 years of age, prior to screening.
Patients
Adults and adolescents (‡ 12 years) with mild to moder-
ate-severe asthma were eligible for enrollment if they had a
history of asthma for ‡ 12 months39 and a documented use of
ICS asthma maintenance therapy for ‡ 4 weeks prior to
screening at a dose not greater than 500 lg/day inhaled
fluticasone or equivalent ICS. Eligible patients had to dem-
onstrate a forced expiratory volume in the first second (FEV1)
of between 40% and 85% (inclusive) of predicted normal
values at both screening and baseline (week 0), following
appropriate withholding of asthma medication. At screening,
patients were required to discontinue any LABA treatment at
least 24hr before the visit for pulmonary function testing and
not use a short-acting bronchodilator as a rescue medication
within 6hr prior to the visit. At baseline, patients were not
permitted to take fluticasone or rescue medication (salbuta-
mol) within 12hr or 6 hr, respectively, before the visit. In ad-
dition, patients had to show a documented reversibility of
‡ 15% in FEV1 within 6 months of screening. During the 14– 3
day run-in period, patients were administered fluticasone by
hydrofluoroalkane (HFA) pressurized metered-dose inhaler
(pMDI) b.i.d. and had to use ‡ 2 inhalations/day of rescue
salbutamol for ‡ 3 days, as well as experience ‡ 1 night with
sleep disturbance or ‡ 3 days with asthma symptoms.AU2c
Exclusion criteria included life-threatening asthma within
12 months, systemic (oral or injectable) corticosteroid medi-
cation within 3 months, omalizumab within 6 months, or
leukotriene receptor antagonist within a week prior to
screening. Patients with an upper or lower respiratory tract
infection within 4 weeks prior to screening or during the run-
in, significant, nonreversible pulmonary disease, a smoking
history (equivalent to 10 pack years, or had smoked within
12 months), or receiving b-blocking agents, tricyclic antide-
pressants, monoamine oxidase inhibitors, astemizole, quini-
dine-type antiarrhythmics, or potent CYP3A4 inhibitors in
the week prior to the screening visit were also excluded.
During the treatment period, fluticasone/formoterol was
administered for either 6 months or 12 months. The treat-
ment period comprised scheduled visits at weeks 2 and 4,
and monthly thereafter. Patients were given a diary card and
a peak flow meter and, during the run-in, entered informa-
tion into an Interactive Voice Response System diary. During
both the run-in and treatment periods, patients recorded
their predose peak expiratory flow rate (PEFR) twice daily,
their daily assessment of asthma symptoms, and daily rescue
medication use.
Interventions
During the 14– 3 day run-in period, patients were assigned
to one of two groups ( b F1Fig. 1) and self-administered fluticasone
(suspension delivered by HFA pMDI) at a dose dependent on
their steroid use prior to screening: those requiring 100–
249lg/day fluticasone (or equivalent) were assigned 100lg/
day fluticasone (one actuation 50lg b.i.d.), whereas those
using 250–500lg/day fluticasone (or equivalent) received
250lg/day fluticasone (one actuation 125lg b.i.d.).
During the treatment period, patients received either flu-
ticasone/formoterol 100/10 lg b.i.d. (HFA suspension; two
actuations 50/5lg, b.i.d.) or 250/10lg b.i.d. (HFA suspen-
sion; two actuations 125/5lg, b.i.d.), depending on whether
they had 100lg/day or 250lg/day ICS during the run-in
period. Study medications were administered via a pMDI
without the use of a spacer, and patients were instructed to
take morning and evening doses timed apart as evenly as
possible. Patients were also required to leave a 1-min interval
between inhalations and wash their mouth thoroughly after
dosing. Rescue salbutamol (100lg/actuation) was available,
as needed, throughout both the run-in and treatment periods.
Safety assessments
Safety assessments included medical history at screening,
physical examinations at screening and baseline, and vital
sign assessments prior to pulmonary function tests (PFTs)
FIG. 1. Study diagram. prn,
as needed.
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and within 30min before the morning dose of study medi-
cation. A safety follow-up, by telephone, took place 2 weeks
after the last dose of treatment. A 12-lead electrocardiogram
(ECG) was performed prior to PFTs at screening and before
morning dosing at each study visit; clinical laboratory tests
were performed at screening, weeks 0 and 4, and months 3,
6, and 12 or at the final visit for patients who discontinued
prematurely. Adverse events (AEs), their severity, outcome,
and relationship to study medication, and the proportion of
patients who were withdrawn because of AEs were recorded
throughout the study period.
Patients were withdrawn if they experienced severe asthma
exacerbations requiring medical intervention. A mild-
to-moderate asthma exacerbation was defined as night
awakenings due to asthma on 2 or more consecutive days, or
the additional use of rescue medication of ‡ 3 inhalations/
day with respect to baseline on 2 or more consecutive days,
or morning predose PEFR > 30% below baseline values on at
least 2 consecutive days. The baseline values for the run-in
period were defined as the PEFR measured at screening; for
the treatment period, this was defined as the average of three
morning PEFR measurements taken at baseline. A severe
asthma exacerbation was defined as the deterioration in
asthma symptoms requiring additional therapy, e.g., a sys-
temic steroid, a visit to the emergency room, or hospitaliza-
tion due to asthma.
Patients were also withdrawn if their prebronchodilatory
FEV1 decreased to < 40% of predicted normal values, pre-
bronchodilator PEFR decreased to £ 75% of baseline average
values on 4 consecutive days, if they used ‡ 12 actuations/
day of rescue salbutamol on ‡ 3 days/week, recorded a sleep
disturbance score of ‡ 3 on three consecutive nights, used
prohibited medications for asthma exacerbations, or experi-
enced a serious or unexpected AE. Patients who withdrew
from the study due to an AE were followed up with ap-
propriate clinical and/or laboratory tests until satisfactory
resolution of the AE.
Patients returned all used and unused study drug to the
site at each visit. During the run-in and treatment periods,
patients recorded the number of inhalations of fluticasone
and the time and number of inhalations of study drug, re-
spectively. At each study visit, the dose counters on the
fluticasone/formoterol inhalers were checked to confirm the
number of actuations taken. Patients with < 70% adherence
to study medication were withdrawn from the study.
Efficacy assessments
Efficacy assessments were the secondary endpoints of this
study and included the spirometry performed at screening,
within 30min before morning dosing, and 1hr after dosing
at each visit during the treatment period. LABA medication
FIG. 2. Patient flow diagram.
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was discontinued at least 24 hr and short-acting b-agonist
medication within 6 hr prior to the first spirometry at
screening, and the use of rescue salbutamol within 6 hr of all
scheduled PFTs. All PFTs were carried out using a spirom-
eter40 and included the forced vital capacity (FVC) (the
maximum volume of air expired as forcefully and as rapidly
as possible after maximum inspiration), PEFR (the maximum
flow rate obtained during the FVC procedure), FEV1, and
FEV1 % predicted based on the patient’s age, height, and
gender, determined according to guidelines for adults ( ‡ 17
years)41 and for adolescents (12–16 years).42
During the study, patients recorded their daily morning
and evening predose PEFR, the time and number of inhala-
tions of both study and rescue medication (patients were to
contact the study site if they had taken 12 or more inhala-
tions of rescue medication on any one day), asthma symptom
scores [from 0 (no symptoms) to 5 (asthma was so severe that
the patient was unable to go to work or school or carry out
normal daily activities)], and sleep disturbance scores [from 0
(patient slept through the night and experienced no asthma)
to 4 (patient could not sleep at all because of asthma)].
Statistical analyses
No statistical analyses were performed on the safety pa-
rameters.
Statistical analyses for FEV1, FVC, and PEFR and the
changes from baseline to each subsequent visit and within
each dose group were analyzed using a paired t test. All
statistical analyses were performed at the 0.05 significance
level unless otherwise noted.
The safety population comprised all enrolled patients who
had at least one inhalation of study medication; the full
analysis set (FAS) included patients in the safety population
with at least one efficacy measurement at baseline and post
baseline, and the per-protocol (PP) population comprised
patients in the FAS without a major protocol violation.
Sample size estimates were not formally calculated but were
Table 1. Patient Demographic and Asthma Characteristics, Safety Population
Fluticasone/formoterol treatment group
100/10 lg b.i.d. 250/10lg b.i.d. Overall
Characteristic Description N= 224a,e N = 248b,f N= 472c,g
Gender, n (%) Male 106 (47.3) 112 (45.2) 218 (46.2)
Female 118 (52.7) 136 (54.8) 254 (53.8)
Ethnic origin, n (%) Caucasian 220 (98.2) 247 (99.6) 467 (98.9)
Black 1 (0.4) 1 (0.4) 2 (0.4)
Asian 3 (1.3) 0 3 (0.6)
Age, years Mean (SD) 39.3 (17.65) 45.2 (15.42) 42.4 (16.76)
Median 39.5 47.0 44.0
Min–Max 12–75 12–79 12–79
Age distribution, n (%) Age 12–17 years 40 (17.9) 16 (6.5) 56 (11.9)
Age 18–79 years 184 (82.1) 232 (93.5) 416 (88.1)
Height, cm Mean (SD) 168.8 (10.17) 168.9 (9.08) 168.8 (9.60)
Median 168.0 169.0 168.0
Min–Max 141–200 150–194 141–200
Weight, kg Mean (SD) 73.5 (17.19) 77.0 (18.33) 75.4 (17.86)
Median 71.0 75.0 73.0
Min–Max 35–131 41–140 35–140
Duration of asthma, years Mean (SD) 12.20 (11.701) 13.04 (10.802) 12.64 (11.233)
Median 7.80 9.60 8.55
Min–Max 1.2–66.7 1.1–64.7 1.1–66.7
FEV1 % predicted
d Mean (SD) 74.0 (9.80) 72.1 (11.01) 73.0 (10.48)
Median 75.0 74.0 74.0
Min–Max 38–99 41–104 38–104
FEV1,
d L Mean (SD) 2.411 (0.6881) 2.269 (0.6327) 2.337 (0.6627)
Median 2.305 2.170 2.250
Min–Max 0.88–4.56 0.96–4.07 0.88–4.56
Reversibility,d % Mean (SD) 27.98 (13.303) 28.25 (14.105) 28.12 (13.709)
Median 22.65 23.30 22.80
Min–Max 14.7–88.0 14.9–116.9 14.7–116.9
N, number of patients in a treatment group; n, number of patients with data available; SD, standard deviation; b.i.d., twice daily.
aN = 213 for weight.
bN= 232 for weight.
cN= 445 for weight.
dFEV1 % predicted and FEV1 are from baseline (week 0), and reversibility is from screening.
eN= 216 for reversibility.
fN= 231 for reversibility.
gN= 447 for reversibility.
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based on the ICH guidelines on the minimum number of
patients required for the long-term treatment of noncritical
conditions.
Results
Overall, 472 patients entered the treatment period and 413
completed the study (F2c Fig. 2). The safety population included
all 472 patients, the FAS contained 466 patients (221 in the
100/10 lg b.i.d. and 245 in the 250/10lg b.i.d. group), and
the PP population included 390 patients. Overall, 77 (16.3%)
patients had a major protocol violation [31 (13.8%) in the
100/10 lg b.i.d. group; 46 (18.5%) in the 250/10 lg b.i.d.
group], including violations of the inclusion/exclusion cri-
teria [51 patients (10.8%)], nonadherence to study medication
[23 patients (4.9%)], the use of prohibited concomitant
medications [4 patients (0.8%)], or failure to withhold specific
medications prior to PFTs [1 patient (0.2%)].
In general, the two treatment groups were well matched
with respect to baseline characteristics (T1c Table 1). The 250/
10 lg b.i.d. treatment arm had a ‡ 5% higher incidence of
patients with a medical history that included abnormalities
in the cardiovascular and genitourinary systems, and the
100/10 lg b.i.d. group had a higher proportion of patients in
the 12–17-year age group compared with the 250/10lg b.i.d.
group (17.9% vs. 6.5%).
Safety and tolerability
The duration of exposure to study medication is presented
inT2c Table 2.
Overall, 174 (36.9%) patients reported AEs (T3c Table 3). The
majority were mild to moderate in severity; those occurring
with an incidence of > 1% are presented inT4c Table 4. The
numbers of patients reporting severe AEs are displayed in
T5c Table 5; asthma was the only severe AE reported by more
than one patient. In total, 18 (3.8%) patients reported AEs
possibly or probably related to study medication, including
asthma (n= 2) and dysphonia (n = 5) reported for more than
one patient.
No deaths were reported. Five patients in each treatment
group experienced a total of 12 serious AEs, all deemed ei-
ther not or unlikely to be study medication–related. Three
patients (1.3%) receiving 100/10lg b.i.d. and 11 (4.4%) re-
ceiving 250/10lg b.i.d. fluticasone/formoterol discontinued
from the study, at least in part, due to an AE; two patients
who received 100/10lg b.i.d. had an asthma exacerbation
and anxiety-induced respiratory syndrome, respectively; six
patients who received 250/10 lg b.i.d. experienced severe
dyspnea during activity, worsening of asthma, a serious
asthma exacerbation, increased breathlessness, increased
asthma symptoms, and upper respiratory tract infection,
respectively.
Six patients had laboratory abnormalities that were mild
to moderate, nonserious AEs: one patient each had increased
white blood cell and neutrophil counts, increased white
blood cell count, increased platelet count, increased aspartate
aminotransferase (AST) and alanine aminotransferase, in-
creased AST, and increased sodium. Four patients had ele-
vated glucose values that met the criteria for potential
clinical significance, three of whom had a history of diabetes,
and all had high plasma glucose levels at each visit, in-
cluding at screening and at baseline.
Three patients reported AEs related to increased blood
pressure: two in the 250/10 lg b.i.d. group reported wors-
ening hypertension (not study medication–related), and one
in the 100/10lg b.i.d. group reported arterial hypertension
(possibly study medication–related). All AEs were assessed
as mild to moderate in severity and resolved or stabilized
with medication.
Four patients had one postbaseline ECG QTcF interval
that was > 500msec, but continued on the study medication
with no subsequent QTcF intervals of > 500msec and with-
out cardiovascular or dysrhythmia events associated with
the QT prolongation. Overall, clinical laboratory tests, vital
sign evaluations, and ECGs showed no abnormal trends or
dose-response–related changes.








Exposure (weeks) N = 224 N = 248 N = 472
Safety population
Mean (SD) 34.04 (13.857) 32.86 (13.674) 33.42 (13.759)
Median 26.00 25.35 25.90
Range 0.1–56.0 0.1–55.7 0.1–56.0
6-month subset N = 124 N = 132 N = 256
Mean (SD) 23.75 (4.855) 23.76 (4.578) 23.75 (4.705)
Median 24.40 24.40 24.40
Range 0.3–30.6 1.3–30.4 0.3–30.6
12-month subset N = 100 N = 116 N = 216
Mean (SD) 46.79 (10.309) 43.21 (13.216) 44.87 (12.065)
Median 49.30 48.80 49.10
Range 0.1–56.0 0.1–55.7 0.1–56.0
N, number of patients in a treatment group; SD, standard
deviation; b.i.d., twice daily.
Table 3. Overview of Adverse Events,
Safety Population









N= 224 N = 248 N = 472
Any adverse event 67 (29.9) 107 (43.1) 174 (36.9)
Any severe adverse event 7 (3.1) 10 (4.0) 17 (3.6)
Any adverse event related
to study druga
5 (2.2) 13 (5.2) 18 (3.8)
Deaths 0 0 0




3 (1.3) 11 (4.4) 14 (3.0)
Any severe asthma
exacerbation
3 (1.3) 6 (2.4) 9 (1.9)
N, number of patients in a treatment group; b.i.d., twice daily.
aInvestigator assessment was possibly or probably related to study
drug.
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Asthma exacerbations
In total, 53 (11.2%) patients reported asthma exacerba-
tions, including 46 (9.7%) reporting mild to moderate exac-
erbations [22 (9.8%) in the 100/10 lg b.i.d. and 24 (9.7%) in
the 250/10lg b.i.d. group] and 9 reporting severe exacer-
bations [1.9%; 3 (1.3%) in the 100/10 lg b.i.d. and 6 (2.4%) in
the 250/10lg b.i.d. group]. One patient administered 100/
10 lg b.i.d. and 3 administered 250/10lg b.i.d. discontinued
prematurely because of asthma, including one as a result of
serious asthma exacerbation.
Efficacy
Efficacy analyses were carried out on the FAS and showed
statistically significant improvements overall and for both
treatment groups for each efficacy assessment (ST1ST4c Supplemen-
tary Tables S1–S4; Supplementary Data are available online at
www.liebertonline.com/jamp). The data shown inF3c Figure 3
illustrate the time bAU3course of pooled efficacy results for all pa-
tients that reached month 12. Data show that, within the first
2 months of treatment, overall efficacy parameters improved
and that good results were sustained throughout the
12-month treatment period.
Discussion
Fluticasone/formoterol combination therapy demon-
strated a good safety and tolerability profile over the
12-month study period. Altogether, 174 patients (36.9%) re-
ported AEs, including 67 (29.9%) in the 100/10lg b.i.d. and
107 (43.1%) in the 250/10lg b.i.d. group, with the majority
either mild or moderate in severity. The incidence of AEs
observed with fluticasone/formoterol in the present study
is in line with that observed in previous long-term studies
of ICS/LABA combinations.43,44 For example, the overall
incidence of AEs was 48.6% with fluticasone propionate/
Table 4. Treatment-Emergent Adverse Events Reported for > 1% in Either Dose Group
or Overall, Safety Population




250/10 lg b.i.d. Overall
System organ class Preferred term N = 224 N= 248 N= 472
Any event 67 (29.9) 107 (43.1) 174 (36.9)
Infections and infestations
Nasopharyngitis 17 (7.6) 28 (11.3) 45 (9.5)
Pharyngitis 6 (2.7) 7 (2.8) 13 (2.8)
Lower respiratory tract infection 5 (2.2) 7 (2.8) 12 (2.5)
Upper respiratory tract infection 6 (2.7) 6 (2.4) 12 (2.5)
Bronchitis 4 (1.8) 5 (2.0) 9 (1.9)
Bronchitis acute 6 (2.7) 3 (1.2) 9 (1.9)
Rhinitis 2 (0.9) 7 (2.8) 9 (1.9)
Acute sinusitis 1 (0.4) 5 (2.0) 6 (1.3)
Sinusitis 1 (0.4) 3 (1.2) 4 (0.8)
Abscess 0 3 (1.2) 3 (0.6)
Respiratory tract infection 3 (1.3) 0 3 (0.6)
Urinary tract infection 0 3 (1.2) 3 (0.6)
Respiratory, thoracic and mediastinal disorders
Dyspnea 5 (2.2) 19 (7.7) 24 (5.1)
Asthmaa 3 (1.3) 9 (3.6) 12 (2.5)
Cough 2 (0.9) 8 (3.2) 10 (2.1)
Dysphonia 1 (0.4) 6 (2.4) 7 (1.5)
Pharyngeal pain 5 (2.2) 1 (0.4) 6 (1.3)
Rhinitis allergic 0 4 (1.6) 4 (0.8)
Nervous system disorders
Headache 7 (3.1) 6 (2.4) 13 (2.8)
Gastrointestinal disorder
Abdominal pain 3 (1.3) 0 3 (0.6)
Musculoskeletal and connective tissue disorders
Pain in extremity 1 (0.4) 3 (1.2) 4 (0.8)
Arthralgia 0 3 (1.2) 3 (0.6)
Eye disorders
Conjunctivitis 2 (0.9) 3 (1.2) 5 (1.1)
Immune system disorders
Seasonal allergy 3 (1.3) 1 (0.4) 4 (0.8)
N, number of patients in a treatment group; b.i.d., twice daily.
aAn asthma exacerbation was considered an adverse event if it did not resolve with the study drug treatments (including salbutamol) and
additional medication was required (e.g., systemic glucocorticosteroids).
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salmeterol xinafoate (250/50lg b.i.d.) and 52.3% with bu-
desonide/formoterol fumarate (200/6 lg once daily or 200/
6–400/12 lg b.i.d.) after 1 year’s treatment in adults with
persistent asthma.43 Thus, the rates of AEs reported here do
not appear to be unusual for combination therapy adminis-
tered over a period of up to 1 year.
The AE profile observed with the fluticasone/formoterol
combination is consistent with that of the individual com-
ponent drugs and in line with those reported for other ICS/
LABA combinations. The most common AEs observed with
fluticasone/salmeterol therapy in a 1-year study were na-
sopharyngitis (13%), upper respiratory tract infection (13%),
and headache, sinusitis, and influenza (each 5%)19,45; the
type and incidence of AEs were similar to those for flutica-
sone alone. The most common treatment-related AEs
reported in previous studies included headache (incidence
1–5%), throat irritation/cough (1–5%), hoarseness/dysphonia
(2–7%), and oropharyngeal candidiasis (1–5%).46 With the
budesonide/formoterol combination, the most common AEs
observed in a 6-month study were respiratory infection
(36%), viral infection (10%), bronchitis, pharyngitis, and
headache (each 6%), and sinusitis, rhinitis, and dysphonia
(each 5%).47 Common treatment-related events reported with
beclometasone/formoterol in a 24-week study include
Table 5. Incidence of Severe Adverse Events, Safety Population





System organ class Preferred term N= 224 N= 248 N = 472
Any event 7 (3.1) 10 (4.0) 17 (3.6)
Infections and infestations
Pneumonia 0 1 (0.4) 1 (0.2)
Herpes zoster 1 (0.4) 0 1 (0.2)
Respiratory, thoracic, and mediastinal disorders
Asthmaa 3 (1.3) 6 (2.4) 9 (1.9)
Dyspnea exertional 0 1 (0.4) 1 (0.2)
Acute respiratory distress syndrome 1 (0.4) 0 1 (0.2)
Gastrointestinal disorder
Pancreatitis acute 1 (0.4) 0 1 (0.2)
General disorders and administrative site conditions
Influenza-like illness 0 1 (0.4) 1 (0.2)
Cardiac disorders
Myocardial infarction 0 1 (0.4) 1 (0.2)
Psychiatric disorders
Mental disorder 0 1 (0.4) 1 (0.2)
Metabolism and nutritional disorders
Diabetes mellitus 1 (0.4) 0 1 (0.2)
N, number of patients in a treatment group; b.i.d., twice daily.
aAn asthma exacerbation was considered an adverse event if it did not resolve with the study drug treatments (including salbutamol) and
additional medication was required (e.g., systemic glucocorticosteroids).
FIG. 3. Summary of efficacy end-
points for patients that reached
month 12. Mean predose FEV1 (L)
and PEFR (L/min) values from day
0 to month 12 are shown.
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headache, hoarseness, and pharyngitis.48 Moreover, com-
parison studies suggest no significant differences in AE profile
between the different ICS/LABA combinations43,44,49,50 or
between ICS/LABA combinations and ICS therapy alone.51,52
In the current study, nasal or oropharyngeal AEs made up
a notable proportion of the AEs. This finding is not unex-
pected given the known oropharyngeal effects of ICS thera-
py.53,54 In the study, the majority ( > 75%) of these events
were mild in severity, none of the events were severe, and
most were not considered related to study medication.
Patients administered fluticasone/formoterol 100/10lg
b.i.d. reported fewer AEs related to the respiratory system
compared with those administered 250/10lg b.i.d., which
may be reflecting differences in the underlying asthma se-
verity between the two groups. The patients assigned to this
treatment group were already receiving 250–500 lg/day
fluticasone (or equivalent) prior to study enrollment com-
pared with those in the 100/10lg b.i.d. group who were
administered 100–249 lg/day fluticasone (or equivalent).
The greater incidence of dysphonia (2.4% vs. 0.4%), for ex-
ample, may have been a consequence of the increased ex-
posure of patients to higher doses of ICS in the 250/10lg
b.i.d. group compared with the 100/10 lg b.i.d. treatment
arm55 and may also have been affected by the fact that
spacers were not used in this study. The laryngeal deposition
of the ICS has been reported to cause the myopathy of the
arytenoid muscles and dysphonia, which seems to be dose-
related.55
No deaths were reported, and the 12 serious AEs experi-
enced by the 10 (2.12%) patients were considered not related
(n = 9) or unlikely related (n = 3) to study medication, in-
cluding three that were respiratory system–related (pneu-
monia, anxiety-induced respiratory syndrome, and asthma
exacerbation).
Asthma exacerbations, principally mild to moderate, were
reported by 53 (11.2%) patients; only 9 (1.9%) experienced
severe exacerbations, with the incidence of severe exacerba-
tions *1% higher in the 250/10 lg b.i.d. than in the 100/
10 lg b.i.d. group (2.4% vs. 1.3%, respectively). It could be
concluded that this is possibly a result of the severity of the
underlying disease in the group receiving the higher dose of
combination therapy.
The clinical assessments and vital signs showed no sig-
nificant or abnormal trends or dose-response changes in ei-
ther treatment group over the 6–12-month period.
The secondary endpoints successfully demonstrated the
efficacy of the combination therapy at both dose strengths.
Clinically important improvements were seen at the a= 0.001
level for mean changes in the predose as well as in the pre-
dose to 1-hr postdose assessments of FEV1, FEV1 % pre-
dicted, PEFR, and FVC measurements: improvements were
observed within a short time period, at each assessment time
point, throughout the treatment period, and for both treat-
ment arms and overall.
As with all chronic diseases, patient adherence to study
medication is an important factor.55–58 Patients in this study
demonstrated good adherence to therapy in both dosage
groups, with only 23 (4.9%) considered protocol violators
because of noncompliance: this is especially noteworthy
considering the study period (up to 12 months). The fact that
patients underwent monthly visits in a clinical trial setting
may have had a positive effect on adherence to study treat-
ment. However, the rapid bronchodilation reported with
fluticasone/formoterol therapy, reflecting the rapid effect of
the formoterol component of the combination,59 could also
be an important factor in improving treatment adherence.
This notion is supported by the fact that nonadherent pa-
tients would improve their adherence if they were able to
feel a therapy working soon after taking it.60,61
The safety and efficacy of both fluticasone and formoterol
are extensively documented in the literature.5,17,32–38 The
administration of fluticasone/formoterol from a single pMDI
allows patients to experience rapid bronchodilation after
dosing while providing sustained anti-inflammatory effects,
via a commonly used and familiar device.26 Together, these
factors may provide incentives for patients to adhere to their
treatment regimen and achieve better asthma control.
In conclusion, this study successfully demonstrated the
long-term safety and efficacy of the new fluticasone/
formoterol combination therapy for patients whose asthma is
not adequately controlled with ICS monotherapy or is al-
ready controlled with an ICS/LABA combination.
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Supplementry Data
Supplementary Table S1. FEV1 (L): Change from Predose at Baseline to Predose Assessments at Each
Visit and 1-hr Postdose at Weeks 2 and 4, and Months 2 and 3, Full Analysis Set
Fluticasone/formoterol 100/10 lg b.i.d. Fluticasone/formoterol 250/10 lg b.i.d. Overall
N= 221 N = 245 N = 466
Visit n Mean (SD) n Mean (SD) n Mean (SD)
Baseline mean
Week 0 221 2.409 (0.6891) 245 2.271 (0.6333) 466 2.34 (0.6632)
Mean change from baseline (week 0)a
Week 2 221 0.198 (0.4139)c 244 0.162 (0.3692)c 465 0.179 (0.3911)c
Week 4 219 0.276 (0.4656)c 241 0.199 (0.3720)c 460 0.236 (0.4204)c
Month 2 215 0.330 (0.4189)c 238 0.231 (0.4515)c 453 0.278 (0.4387)c
Month 3 215 0.349 (0.4571)c 234 0.211 (0.4113)c 449 0.277 (0.4388)c
Month 4 212 0.375 (0.4531c 233 0.228 (0.4165)c 445 0.298 (0.4400)c
Month 5 210 0.405 (0.4911)c 230 0.239 (0.4144)c 440 0.319 (0.4596)c
Month 6 207 0.376 (0.4847)c 227 0.239 (0.4301)c 434 0.304 (0.4616)c
Month 7 91 0.414 (0.5802)c 97 0.222 (0.5097)c 188 0.315 (0.5519)c
Month 8 90 0.426 (0.5564)c 93 0.287 (0.4785)c 183 0.355 (0.5215)c
Month 9 90 0.409 (0.6204)c 92 0.268 (0.4409)c 182 0.338 (0.5404)c
Month 10 90 0.436 (0.5862)c 90 0.234 (0.4226)c 180 0.335 (0.5196)c
Month 11 89 0.461 (0.5378)c 90 0.213 (0.4751)c 179 0.336 (0.5209)c
Month 12 87 0.462 (0.5558)c 88 0.241 (0.4611)c 175 0.351 (0.5208)c
Final visitb 220 0.381 (0.4875)c 242 0.236 (0.4336)c 462 0.305 (0.4652)c
FEV1: Change from predose at baseline (week 0) to 1 hr postdose assessment
Visit n
Mean change from
baseline (week 0) (SD)a n
Mean change from
baseline (week 0) (SD)a n
Mean change from
baseline (week 0) (SD)a
Week 2 218 0.466 (0.4492)c 240 0.379 (0.3829)c 458 0.420 (0.4175)c
Week 4 217 0.508 (0.4570)c 234 0.407 (0.4338)c 451 0.455 (0.4475)c
Month 2 213 0.524 (0.4527)c 234 0.417 (0.4660)c 447 0.468 (0.4623)c
Month 3 215 0.526 (0.4880)c 233 0.392 (0.4378)c 448 0.456 (0.4669)c
N, number of patients in a treatment group; SD, standard deviation; b.i.d., twice daily.
aPaired t test performed on observed data for full analysis set.
bThe final visit occurred at month 6 or month 12 for patients who completed the study, depending on the study subset; or upon early
discontinuation.
cIndicates a statistically significant change from baseline (week 0) at the a= 0.001 level.
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Supplementary Table S2. FEV1 % Predicted: Change from Predose at Baseline to Predose Assessments
at Each Visit and 1-hr Postdose at Weeks 2 and 4, and Months 2 and 3, Full Analysis Set
Fluticasone/formoterol 100/10 lg b.i.d. Fluticasone/formoterol 250/10 lg b.i.d. Overall
N = 221 N = 245 N= 466
Visit n Mean (SD) n Mean (SD) n Mean (SD)
Baseline mean
Week 0 221 74.1 (9.64) 245 72.3 (10.86) 466 73.2 (10.33)
Mean change from baseline (week 0)a
Week 2 221 5.9 (11.91)c 244 5.0 (11.54)c 465 5.4 (11.71)c
Week 4 219 8.1 (13.05)c 241 6.4 (11.63)c 460 7.2 (12.34)c
Month 2 215 9.9 (12.12)c 238 7.3 (13.31)c 453 8.5 (12.81)c
Month 3 215 10.4 (13.06)c 234 6.7 (12.56)c 449 8.5 (12.92)c
Month 4 212 11.3 (13.16)c 233 7.3 (13.01)c 445 9.2 (13.22)c
Month 5 210 12.0 (13.96)c 230 7.5 (12.98)c 440 9.7 (13.62)c
Month 6 207 11.3 (13.63)c 227 7.5 (13.53)c 434 9.3 (13.69)c
Month 7 91 12.1 (16.38)c 97 7.2 (15.42)c 188 9.6 (16.04)c
Month 8 90 12.5 (16.01)c 93 8.9 (14.52)c 183 10.7 (15.34)c
Month 9 90 11.9 (17.49)c 92 8.3 (13.86)c 182 10.1 (15.82)c
Month 10 90 12.8 (16.33)c 90 7.3 (12.73)c 180 10.0 (14.85)c
Month 11 89 13.5 (15.42)c 90 6.9 (14.58)c 179 10.2 (15.32)c
Month 12 87 13.7 (16.01)c 88 7.3 (14.04)c 175 10.5 (15.35)c
Final visitb 220 11.5 (13.84)c 242 7.4 (13.63)c 462 9.3 (13.87)c
FEV1 % predicted: change from predose at baseline to 1 hr postdose assessment
Visit n
Mean change from
baseline (week 0) (SD)a n
Mean change from
baseline (week 0) (SD)a n
Mean change from
baseline (week 0) (SD)a
Week 2 218 14.2 (12.89)c 240 11.8 (11.22)c 458 12.9 (12.09)c
Week 4 217 15.4 (12.78)c 234 12.9 (13.20)c 451 14.1 (13.05)c
Month 2 213 15.9 (13.00)c 234 13.2 (13.88)c 447 14.5 (13.52)c
Month 3 215 15.9 (13.45)c 233 12.5 (13.99)c 448 14.1 (13.82)c
N, number of patients in a treatment group; SD, standard deviation; b.i.d., twice daily.
aPaired t test performed on observed data for full analysis set.
bThe final visit occurred at month 6 or month 12 for patients who completed the study, depending on the study subset; or upon early
discontinuation.
cIndicates a statistically significant change from baseline/week 0 at the a= 0.001 level.
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Supplementary Table S3. PEFR (L/MIN): Change from Predose at Baseline to Predose Assessments
at Each Visit and 1-hr Postdose at Weeks 2 and 4, and Months 2 and 3, Full Analysis Set
Fluticasone/formoterol 100/10 lg b.i.d. Fluticasone/formoterol 250/10lg b.i.d. Overall
N= 221 N = 245 N = 466
Visit n Mean (SD) n Mean (SD) n Mean (SD)
Baseline mean
Week 0 221 321.5 (102.89) 245 318.7 (101.40) 466 320.0 (102.00)
Mean change from baseline (week 0)a
Week 2 221 27.2 (73.41)c 244 28.2 (82.69)c 465 27.7 (78.34)c
Week 4 219 39.3 (74.51)c 241 38.7 (86.00)c 460 39.0 (80.65)c
Month 2 215 48.1 (80.83)c 238 40.9 (96.79)c 453 44.3 (89.55)c
Month 3 215 53.8 (78.26)c 234 37.5 (93.28)c 449 45.3 (86.71)c
Month 4 212 57.5 (79.61)c 233 43.0 (92.76)c 445 49.9 (86.95)c
Month 5 210 64.9 (77.68)c 230 48.8 (96.48)c 440 56.5 (88.28)c
Month 6 207 64.8 (78.96)c 227 47.0 (95.22)c 434 55.5 (88.19)c
Month 7 91 69.9 (95.93)c 97 46.0 (92.34)c 188 57.6 (94.61)c
Month 8 90 80.0 (94.55)c 92 58.2 (99.13)c 182 69.0 (97.24)c
Month 9 90 72.7 (95.24)c 92 54.2 (88.36)c 182 63.3 (92.04)c
Month 10 90 80.6 (98.22)c 90 52.1 (83.80)c 180 66.4 (92.16)c
Month 11 89 85.1 (100.58)c 90 44.6 (87.28)c 179 64.8 (96.04)c
Month 12 87 82.4 (94.19)c 88 57.4 (90.06)c 175 69.8 (92.73)c
Final visitb 220 67.4 (81.62)c 242 51.0 (92.05)c 462 58.8 (87.52)c
PEFR (L/min): change from predose at baseline to 1 hr postdose assessment
Visit n
Mean change from
baseline (week 0) (SD)a n
Mean change from
baseline (week 0) (SD)a n
Mean change from
baseline (week 0) (SD)a
Week 2 218 65.6 (78.64)c 240 62.3 (79.29)c 458 63.9 (78.91)c
Week 4 217 78.3 (73.31)c 234 68.3 (87.78)c 451 73.1 (81.21)c
Month 2 213 78.6 (80.92)c 234 74.0 (98.57)c 447 76.2 (90.52)c
Month 3 215 80.9 (77.27)c 232 68.1 (94.90)c 447 74.3 (87.01)c
N, number of patients in a treatment group; SD, standard deviation; b.i.d., twice daily.
aPaired t test performed on observed data for full analysis set.
bThe final visit occurred at month 6 or month 12 for patients who completed the study, depending on the study subset; or upon early
discontinuation.
cIndicates a statistically significant change from baseline (week 0) at the a= 0.001 level.
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Supplementary Table S4. FVC (L): Change From Predose at Baseline to Predose Assessments
at Each Visit and 1-hr Postdose at Weeks 2 and 4, and Months 2 and 3, Full Analysis Set
Fluticasone/formoterol 100/10 lg b.i.d. Fluticasone/formoterol 250/10 lg b.i.d. Overall
N= 221 N= 245 N = 466
Visit n Mean (SD) n Mean (SD) n Mean (SD)
Baseline mean
Week 0 221 3.188 (0.8997) 245 3.123 (0.8614) 466 3.154 (0.8794)
Mean change from baseline (week 0)a
Week 2 221 0.179 (0.5161)c 244 0.169 (0.4444)c 465 0.174 (0.4793)c
Week 4 219 0.259 (0.5167)c 241 0.206 (0.4532)c 460 0.231 (0.4847)c
Month 2 215 0.324 (0.5150)c 238 0.228 (0.5188)c 453 0.274 (0.5187)c
Month 3 215 0.328 (0.5621)c 234 0.208 (0.5036)c 449 0.266 (0.5352)c
Month 4 212 0.369 (0.5647)c 233 0.249 (0.5376)c 445 0.306 (0.5533)c
Month 5 210 0.410 (0.5577)c 230 0.258 (0.5396)c 440 0.330 (0.5529)c
Month 6 207 0.380 (0.5457)c 227 0.246 (0.5289)c 434 0.310 (0.5406)c
Month 7 91 0.396 (0.6033)c 97 0.302 (0.5985)c 188 0.348 (0.6011)c
Month 8 90 0.406 (0.6294)c 93 0.343 (0.6006)c 183 0.374 (0.6140)c
Month 9 90 0.361 (0.6652)c 92 0.314 (0.5756)c 182 0.337 (0.6202)c
Month 10 90 0.433 (0.6368)c 90 0.313 (0.5841)c 180 0.373 (0.6123)c
Month 11 89 0.454 (0.5684)c 90 0.294 (0.5949)c 179 0.374 (0.5858)c
Month 12 87 0.435 (0.6468)c 88 0.309 (0.5686)c 175 0.372 (0.6103)c
Final visitb 220 0.371 (0.5754)c 242 0.235 (0.5247)c 462 0.300 (0.5530)c
FVC (L): change from predose at baseline to 1 hr postdose assessment
Visit n
Mean change from
baseline/week 0 (SD)a n
Mean change from
baseline/week 0 (SD)a n
Mean change from
baseline/week 0 (SD)a
Week 2 218 0.418 (0.5305)c 240 0.339 (0.4225)c 458 0.377 (0.4780)c
Week 4 217 0.435 (0.5043)c 234 0.367 (0.4930)c 451 0.399 (0.4991)c
Month 2 213 0.465 (0.5463)c 234 0.392 (0.4970)c 447 0.427 (0.5218)c
Month 3 215 0.467 (0.5664)c 233 0.336 (0.4986)c 448 0.399 (0.5356)c
N, number of patients in a treatment group; SD, standard deviation; b.i.d., twice daily.
aPaired t test performed on observed data for full analysis set.
bThe final visit occurred at month 6 or month 12 for patients who completed the study, depending on the study subset; or upon early
discontinuation.
cIndicates a statistically significant change from baseline (week 0) at the a = 0.001 level.
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